Akut Miyeloid Lösemili Hastaların Pekiștirme Tedavisinde Hematopoetik Büyüme Faktörü Kullanımının Maliyet Etkinliği
Abstract
Aim: Acute myeloblastic leukemia (AML) is a malign and clonal disease of the bone marrow resulting in neoplastic conversion of hematopoietic progenitor cells. This study was planned to evaluate effects of G-CSF use on neutropenia duration, infection frequency, febrile neutropenia duration, duration of antibiotic and/or antifungal use and cost in AML treatment
References
- Liesvelt JL, Lichtman MA. Acute myelogenous leukemia. In: Beutler E, Lichtman MA, Coller BC, Kipps TJ, editors. Williams Hematology. 5th ed. New York: McGraw – Hill Book Co.:1995. pp 1183 -1236.
- Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675- 36
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2001;34:730-751,
- Ottmann OG, Bug G, Krauter J. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 2007;44:183 – 192.
- Moore JO, Dodge RK, Amrein PC, et al. Granulocyte colony- stimulating factor (Filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl recombinant human granulocyte benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 1997;89:780-788.
- Takeshita A, Ohno R, Hirashima K, et al. A randomized double- blind controlled study of patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. Rinsho Ketsueki 1995;36:606-614.
- Standaert B, Goldstone J, Lu ZJ, et al. Economic analysis of filgrastim use for patients with acute myeloid leukemia in the UK. Pharmacoeconomics 2007;20:665- 6
- Bradley AM, Deal AM, Buie LW, et al. Neutropenia-associated outcomes in adults with acute myeloid leukaemia receiving vytarabine consolidation chemotherapy with or without granu-locyte colony-stimulating factor. Pharmacotherapy 2012;32:1070-1077abs.
- Alvrado Ibarra ML, Borbolla Escoboza JR, López-Hernández MA, et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Rev Invest Clin 1999;51:77-80.
Akut Miyeloid Lösemili Hastaların Pekiștirme Tedavisinde Hematopoetik Büyüme Faktörü Kullanımının Maliyet Etkinliği
Abstract
Amaç: Akut miyeloid lösemi (AML) kemik iliğinin habis ve klonal bir hastalığı olup hematopoetik
öncül hücrelerin neoplastik dönüșümü ile gelișir. Bu çalıșma; AML tedavisinde kullanılan G-CSF’ün
nötropeni süresi, enfeksiyon sıklığı, febril nötropeni süresi, antibiyotik ve/veya antifungal kullanım
süresi ve maliyet üzerine etkisini araștırmak üzere planlandı.
Yöntemler: Çalıșmaya toplam 40 hasta alındı (19 kadın, 21 erkek, yaș ortalaması 42). Hastalar G-CSF
kullanılan ve kullanılmayan iki gruba ayrıldı. Nötropeni gelișme zamanı, nötropeni süresi, ateșin
ortaya çıkıș zamanı, ateșin süresi, kültürle ispatlanan enfeksiyon, antibiyotik ve antifungal kullanım
süresi, hastanede yatıș süresi, antibiyoterapi maliyeti ve toplam maliyet verileri iki grup arasında
kıyaslandı.
Bulgular: G-CSF grubunda; nötropeni süresi, ateș ortaya çıkıș zamanı, hastane yatıș süresi, ateș süresi,
antibiyotik ve antifungal tedavi süresi ve antibiyoterapi maliyeti azaldı. G-CSF grubunda;
antibiyoterapi dıșı günlük hastane maliyeti ve toplam maliyette hafif azalma mevcuttu (P: 0,751).
Sonuç: AML’li hastaların pekiștirme tedavisinde kullanılan yüksek doz ARA-C protokolüne G-CSF
grubunda eklenmesi nötropeni ve hastanede yatıș süresini anlamlı olarak kısaltır (p
References
- Liesvelt JL, Lichtman MA. Acute myelogenous leukemia. In: Beutler E, Lichtman MA, Coller BC, Kipps TJ, editors. Williams Hematology. 5th ed. New York: McGraw – Hill Book Co.:1995. pp 1183 -1236.
- Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675- 36
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2001;34:730-751,
- Ottmann OG, Bug G, Krauter J. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 2007;44:183 – 192.
- Moore JO, Dodge RK, Amrein PC, et al. Granulocyte colony- stimulating factor (Filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl recombinant human granulocyte benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 1997;89:780-788.
- Takeshita A, Ohno R, Hirashima K, et al. A randomized double- blind controlled study of patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. Rinsho Ketsueki 1995;36:606-614.
- Standaert B, Goldstone J, Lu ZJ, et al. Economic analysis of filgrastim use for patients with acute myeloid leukemia in the UK. Pharmacoeconomics 2007;20:665- 6
- Bradley AM, Deal AM, Buie LW, et al. Neutropenia-associated outcomes in adults with acute myeloid leukaemia receiving vytarabine consolidation chemotherapy with or without granu-locyte colony-stimulating factor. Pharmacotherapy 2012;32:1070-1077abs.
- Alvrado Ibarra ML, Borbolla Escoboza JR, López-Hernández MA, et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Rev Invest Clin 1999;51:77-80.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | February 1, 2013 |
| Published in Issue | Year 2013 Volume: 66 Issue: 2 |